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Abstract: The heart carries out its pumping function by converting the chemical energy stored in fatty acids and glucose 
into the mechanical energy of actin-myosin interaction of myofibrils. Development of congestive heart failure is usually 
preceded by a period of compensated left ventricular hypertrophy (LVH) and alterations in myocardial bioenergetics have 
been considered to play an important role in this transition. Myocardial energetic state that is reflected by the ratio of 
Phosphocreatine to Adenosine Triphosphate (PCr/ATP) is significantly decreased in hearts with LVH. The severity of this 
abnormality is linearly related to the severity of cardiac hypertrophy as well as left ventricular (LV) dysfunction, and is 
independent of a persistent myocardial ischemia. The decrease in PCr/ATP is accompanied by a decrease in creatine 
kinase flux and alterations in substrate utilization in LVH hearts. Moreover, there is a profound heterogeneity in 
alterations in myocardial energy metabolism in hearts with post-infarction hypertrophy with the most severe abnormality 
present in the inner layers of the periscar border zone (BZ). This review will discuss various aspects of myocardial 
energetics in animal models of three different types of LVH (pressure-overload, volume overload and post-infarction) 
with a brief description of myocardial energetics in humans with LVH.  
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INTRODUCTION 
  Cardiac energy metabolism has three components. The 
first is substrate utilization which involves the cellular 
uptake of substrates (mainly fatty acids and glucose) and 
their breakdown by beta-oxidation and glycolysis resulting 
in the formation of acetyl coenzyme A (CoA), which is fed 
into the Krebs cycle and produces Nicotinamide Adenine 
Dinucleotide (NADH) and carbon dioxide (CO2). The 
second component is oxidative phosphorylation which 
involves transfer of electrons from NADH to oxygen through 
the mitochondrial respiratory chain that creates a proton 
electrochemical gradient across the inner mitochondrial 
membrane subsequently driving the F1-F0 ATP synthase to 
produce Adenosine Triphosphate (ATP) by phosphorylating 
Adenine Diphosphate (ADP). The third component is ATP 
transfer and utilization that involves the creatine kinase 
shuttle.  
  Derangements in cardiac energy metabolism occur with 
the development of left ventricular hypertrophy (LVH). LVH 
is a manifestation of cardiac remodeling and has been 
classified into pressure overload hypertrophy, volume 
overload hypertrophy and post-infarction hypertrophy. LVH 
is initially adaptive but ultimately leads to maladaptive 
hypertrophy and transition to congestive heart failure (CHF). 
The exact mechanisms underlying this transition from 
compensated LVH to CHF are likely multifactorial but 
alterations in myocardial bioenergetics have been considered 
to play an important role. 
  The principal method for studying myocardial energy 
metabolism in vivo is through Nuclear Magnetic Resonance 
(NMR) spectroscopy. Our laboratory has specialized in 
performing in vivo NMR spectroscopy in large animals to   
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study abnormalities in high energy phosphate metabolism, 
oxidative phosphorylation, creatine kinase kinetics and flux 
and substrate utilization. In this review, we will focus on the 
myocardial energetics in different animal models of 
ventricular hypertrophy (summarized in Table 1). 
PRESSURE OVERLOAD HYPERTROPHY 
Animal Model 
  Pressure overload hypertrophy leads to concentric 
hypertrophy due to an increase in wall thickness that can be 
seen clinically in patients with hypertension or aortic 
stenosis. Different animal models have been used to create 
pressure overload leading to concentric hypertrophy. The 
degree of ventricular hypertrophy varies in these models and 
thus the results of the studies vary slightly. The most 
commonly used method is placement of a constrictor band 
around the ascending aorta to cause an increase of left 
ventricular systolic pressure.  
High Energy Phosphate Levels 
  In our laboratory, we placed constrictor bands on the 
ascending aorta in young 8 week old dogs to create a peak 
systolic pressure gradient of approximately 20-30mmHg 
across the stenosis [1]. The pressure overload then increased 
progressively as the degree of aortic narrowing remained 
fixed in the face of normal body growth. After a follow-up of 
1 year, LVH expressed as a ratio of left ventricular weight to 
body weight (LVW/BW) was significantly higher in the 
banded dogs as compared to normal controls (8.9±0.7 g/kg
vs. 4.3±0.14 g/kg, p< 0.01) which represented a doubling of 
the relative LV mass in the banded dogs [1]. None of the 
animals developed clinical evidence of heart failure. There 
was a significant decrease in high energy phosphates and 
PCr/ATP ratio in the LVH dogs under baseline conditions 
[1]. Specifically, ATP was decreased by 42%, Creatine 
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comparison with normal dogs. There was a transmural 
gradient with PCr/ATP ratios of 1.62±0.15, 1.61±0.11 and 
1.43±0.06 in the subepicardium, midwall and subendocar-
dium respectively. These energetic abnormalities were 
proportional to the degree of hypertrophy. Moreover, ADP 
levels calculated from the creatine kinase equilibrium 
increased proportionally with the severity of LVH. These 
high energy phosphate (HEP) abnormalities were not 
corrected by pharmacological vasodilatation with adenosine, 
thus implying that these energetic changes are not due to 
persistent hypoperfusion [1]. When the hypertrophied heart 
was placed under stress with atrial pacing at 200 and 240 
bpm, there was a further decrease in the creatine phosphate 
and accumulation of inorganic phosphate in the endocardial 
layers and this correlated with a decreased blood flow in 
these layers. These pacing induced abnormalities were not 
seen in normal hearts.  
  Using a similar method of aortic banding in adult dogs, 
moderate LVH can be created [2]. In these dogs, a pressure 
gradient of about 50mmHg was created across the narrowing 
and the dogs were followed for about 2 months. This 
resulted in a LVW/BW of 5.7±0.19g/kg in the banded dogs 
which was 32% greater than normal animals [2]. In these 
dogs, the basal HEP levels and PCr/ATP ratio was normal as 
compared to the abnormal values in the severe LVH model 
mentioned above. However, pacing at 240 bpm resulted in 
similar decline in PCr and accumulation of inorganic 
phosphate (Pi) in the subendocardial layers. This was also 
associated with a relatively decreased blood flow to the 
endocardial layers. Dobutamine had a positive chronotropic 
and inotropic effect leading to greater increases in rate 
pressure product (RPP) in hypertrophied hearts as compared 
to normal which was associated with greater decreases in 
PCr/ATP that were uniform across the LV wall. When the 
dose of dobutamine was increased in normal animals to 
increase the RPP to similar amounts as the LVH animals, 
similar decreases in HEP levels was noted. Thus, 
dobutamine induced HEP abnormalities seem to be related to 
the increase in workload in these animals. 
Myocardial Oxygenation 
  Although, there was a relatively decreased blood flow to 
the endocardium with pacing in the above studies, it still 
does not imply that these tissues are ischemic. In another 
study, moderate LVH was created in young 2- 4 week old 
pigs with ascending aortic banding to create a systolic 
pressure gradient of 20mmHg [3]. This produced a 38% 
increase in LVW/BW after approximately 3 months. 
Coronary reserve, as assessed by the ratio of blood flow 
during adenosine infusion to baseline blood flow, was 
significantly lower in the LVH pigs compared with controls 
(3.5±0.4 vs. 5.5±0.4 mL/g · min, p<0.05); however, 
transmural myocardial bloodflow was similar in both groups 
of pigs, both at baseline and with dobutamine stimulation, 
probably reflecting the higher coronary perfusion pressure in 
the LVH pigs. The PCr/ATP ratio tended to be lower in the 
LVH animals at baseline but both groups had a similar 
decline in the PCr/ATP ratio with dobutamine stimulation. 
Moreover, anterior wall lactaterelease did not differ between 
the groups at baseline, nor did the increase in lactate release 
differ during dobutamine stimulation. Thus, despite their 
reduced coronary vasodilator reserve and the absence of a 
greater rise in myocardial blood flow to compensate for a 
substantially higher LV double product, pigs with moderate 
LVH did not exhibit a greater susceptibility to myocardial 
ischemia during dobutaminestress [3].  
Table 1. Myocardial Energetics in Different Animals Models of Left Ventricular Hypertrophy 
Pressure Overload Hypertrophy  Volume Overload Hypertrophy  Post-infarction Hypertrophy 
PCr/ATP under baseline conditions Decreased in severe LVH but normal
in moderate LVH. 
Decreased Decreased 
PCr/ATP under increased 
workload 
Decreased in both moderate and 
severe LVH. 
No further decrease in PCr/ATP 
from baseline. 
Decreased 
Regional heterogeneity in 
PCr/ATP 
Worse in subendocardium.  -  Worse in the borderzone 
subendocardium 
Are changes in PCr/ATP due to 
ischemia? 
No No  No 
CK forward rate constant  No change  -  No change 
CK flux rate  Decreased  -  Decreased 
Total CK activity  Normal  -  Normal 
CK-MM isoform  Decreased  -  Decreased 
CK-mitochondrial isoform  Decreased  -  Decreased 
CK-MB isoform  Increased  -  Increased 
Fatty acid oxidation  Decreased  Increased  No change 
Glycolysis Increased  -  Increased 
Glucose oxidation  Increased probably through 
anaplerotic pathways 
- Increased 
PCr, Phosphocreatine; ATP, Adenosine Triphosphate; CK, Creatine Kinase. Myocardial Energetics in Left Ventricular Hypertrophy  Current Cardiology Reviews, 2009, Vol. 5, No. 3     245
  It could still be argued that the HEP abnormalities seen in 
LVH hearts at baseline and higher work state are the result of 
impaired diffusion of oxygen to the cells. It has been 
observed that the intercapillary distances in hearts with 
pressure overload are increased. This is due to the fact that 
the capillary:myocyte ratio remains unchanged while the 
myocyte diameter increases. So, the oxygen diffusion 
distance is greater in hypertrophied hearts as compared to 
normal resulting in the possibility of oxygen deficiency at 
the mitochondria with no abnormality in the blood flow 
rates. H1 NMR spectroscopy has been used to quantitate the 
degree of myoglobin deoxygenation in myocytes and thus 
determine the intracellular oxygen tension. Using this 
technique, it has been demonstrated that the abnormally 
decreased PCr/ATP ratio found in severely hypertrophied
myocardium during basal conditions cannot be ascribed to 
inadequate myocyte oxygen availability [4]. Secondly, the 
more prominent HEP changes during catecholamine
stimulation in hypertrophied hearts are not associated with
detectable deoxymyoglobin, thus failing to support impaired 
oxygen diffusion as a limiting factor in the hypertrophied 
myocardium [4]. 
Myocardial Creatine Kinase Kinetics and Isoform 
Expression 
  The creatine kinase (CK) system plays an important role 
in myocardial energy metabolism by maintaining ADP levels 
high at the mitochondria, where ATP is generated and low at 
sites of ATP utilization [5]. Decreases of CK activity have 
the potential of affecting myocardial performance. In a 
canine model, ascending aortic banding in 8 week old dogs 
resulted in severe LV hypertrophy with LVW/BW of 
9.45±0.63g/kg which was 92% greater than normal animals 
[6]. This resulted in significant decrease in myocardial PCr, 
creatine, and PCr/ATP as well as a 30% decrease in ATP. 
This was associated with a 40% decrease in CK-MM 
isoform mRNA and 50% decrease in CK-MM isoform 
protein and 20% decrease in CK-mitochondrial protein. On 
the other hand, CK-MB isoform mRNA was significantly 
increased and the CK-MB protein level was increased 10 
fold as compared to normal animals. The CK-MB isoform 
increase in models of LVH cannot be merely attributed to a 
compensatory increase as a result of the decrease in CK-MM 
isoform as deletions of CK-MM and CK-mitochondria in 
isolated perfused mice heart models did not result in an 
increase in CK-MB protein [7]. Similarly, this fetal shift 
does not seem to offer any kinetic advantage as the CK 
velocity/CK Vmax in vivo was similar for CK-MB and CK-
MM [7]. It could be a result of the hemodynamic overload 
on the LV or the consequent myocyte hypertrophy. 
  Total CK activity remained normal; however this does 
not take into account the CK compartmentalization within 
the cell. The higher CK-MB levels may contribute to total 
CK activity but CK-MB is not compartmentalized like CK-
MM or CK-mitochondria within the cell. CK forward rate 
constant was not different in LVH animals but the CK 
forward flux rate was decreased by 60% in LVH and further 
decreased during dobutamine stimulation. The myocardial 
free ADP was increased in LVH animals. The increased 
ADP in association with a lower CK flux rate in the 
hypertrophied hearts mirrors similarresponses to increases of 
workload that occur in the fetal or newborn heart and are 
consistent with the concept that an alteration in the pathway 
for mitochondrial regulation exists in the hypertrophied
hearts that is similar to that in the less ordered fetal or 
neonatalheart. However, the CK flux rate was still 7-8 times 
higher than the ATP utilization rate and thus did not result in 
impairment of LV contractile function as shown by the 
increase in the LV systolic pressure and rate of ATP 
synthesis (MvO2) in response to dobutamine. Similar 
increases in CK-MB, decrease in the sum of CK-MM and 
CK-mitochondria with normal total CK activity have been 
found in a rat model of moderate LV hypertrophy (30% 
increase in LVW/BW) [8]. 
Oxidative Capacity 
  Although myocardial HEP metabolism is abnormal in 
hearts with pressure overload hypertrophy and failure, it is 
unclear whether this is associated with impaired oxidative 
capacity. Mitochondrial uncoupling agent 2,4-dinitrophenol 
(DNP) has been used to determine whether the hypertrophied 
and failing hearts have reserve oxidative capacity during the 
high workload produced by catecholamine infusion [9]. This 
revealed that DNP increased MvO2 in swine with 
compensated hypertrophy but failed to do so in swine with 
overt heart failure. At the same time PCr/ATP was 
maintained in compensated hypertrophy while it decreased 
further in heart failure. Therefore, primary abnormalities of 
oxidative ATP production did not constrain contractile 
performance at moderately high workloads in hearts with 
compensated pressure overload hypertrophy, while the 
capacity of some rate limiting reaction in the oxidative ATP 
synthetic pathway may have been reached in swine with 
heart failure at high cardiac workstates. 
Substrate Utilization 
  Alterations of substrate metabolism have been reported in 
several models of LVH and failing hearts. Glucose and fatty 
acid (FA) oxidation was measured ex vivo in the 
spontaneously hypertensive rat (SHR) model of LVH [10]. 
These 15 week old rats had higher systolic blood pressures 
(189±8 vs. 139±7 mmHg) and LVH (HW/BW was 
5.19±0.24 vs. 3.93±0.14 mg/g). The results revealed that FA 
oxidation of SHR hearts is profoundly suppressed (60-80%) 
relative to that of the normotensive Sprague Dawley (SD) 
strain, particularly at high workloads. Glucose oxidation is 
also moderately elevated, yielding a marked (four-to-five-
fold) increase in the ratio of glucose/FA oxidation rates in 
the SHR hearts. Since more ATP is generated per mole of 
oxygen consumed when glucose is the fuel source, these 
results are consistent with the hypothesis that a shift away 
from FA use toward glucose contributes to the preservation 
of energetic economy in stable, concentric LVH.  
  Accumulation of 2-deoxyglucose (2-DG) can be used as 
a surrogate of glucose uptake. Using intracoronary infusion 
of 2-DG, our group has shown that the severe pressure-
overloaded hypertrophied myocardium accumulated   
31P NMR–detectable 2DGP but normalmyocardium did not, 
and that 2DGP accumulation in the hypertrophiedhearts was 
greatest in the subendocardium [11]. Accumulation of 2DGP
was related to the presence of myocardial hypertrophy and 
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of left ventricular systolic pressure in normal hearts did not
result in detectable accumulation of 2DGP [11]. In another 
study of moderate LVH in pigs, the uptake of glucose, 
lactate, and free fatty acids did not differ between the groups 
in the basal state [3]. However, during dobutamine 
stimulation, glucose uptake was greater in the LVH group 
(0.84 +/- 0.09 mumol/g.min vs. 0.59 +/- 0.08 mumol/g.min, 
P <.05). In a subset of animals, 14C-glucose was used to 
assess glucose oxidation. These data showed that the LVH 
animals had a greater rate of glucose oxidation (0.6 +/- 0.10
vs. 0.28 +/- 0.08 mumol/g.min, P <.05) and a greater rate of 
glucose conversion to lactate (0.20 +/- 0.04 versus 0.09 +/- 
0.02 mumol/g.min, P < .05) compared with the control pigs. 
Thus, LVH pigs exhibited significantly greater use of 
exogenous glucose during dobutamine stress, as evidenced
by increases in both glucose oxidation and anaerobic 
glycolysis. The increased myocardial free ADP levels seen 
in models of pressure overload hypertrophy can be partly 
explained by a change in substrate utilization in LVH 
animals. A decrease in fatty acid utilization and increase in 
glycolysis may result in lower NADH levels and lower 
NADH generation that would require a higher cytosolic ADP 
to drive ATP production to a level necessary to maintain the 
ATP utilization rate.  
  It has also been shown that the reduction in fatty acid 
oxidation in hypertrophied hearts is accompanied by an 
increase in a compensatory metabolic pathway referred to as 
anaplerosis (filling up of the tricarboxylic acid (TCA) cycle) 
that provides an alternate route for glucose oxidation [12]. 
Transverse aortic constriction in rats resulted in 63% LVH 
after 10 weeks and 13C NMR spectroscopy was then used to 
study the oxidative metabolism in these isolated hearts that 
were perfused with palmitate and glucose. PCr/ATP ratio 
was decreased by 30% which was accompanied by a 
decrease in fatty acid oxidation. Flux through carnitine 
palmitoyltransferase I (CPT-I) was 23% lower in 
hypertrophied hearts at similar TCA cycle rates and was 
accompanied by a shift towards increased expression of the
L–CPT I isoform (Liver isoform as compared to muscle 
isoform). Moreover, glucose oxidation via pyruvate 
dehydrogenase complex to produce acetyl CoA did not 
compensate for reduced palmitate oxidation rates. However, 
hypertrophied rats displayed an 83% increase in anaplerotic 
flux into the TCA cycle that was supported by conversion of 
glycolytic pyruvate into malate by malic enzyme whose 
levels were also increased. This increased oxidation of 
glucose through anaplerosis is inherently inefficient leading 
to decreased production of NADH. 
  Recent advances in molecular biology have enabled us to 
study the molecular mechanisms underlying the observed 
substrate switch in pressure overload hypertrophy. These 
studies have revealed the importance of peroxisome 
proliferator-activated receptor gamma co-activator (PGC-1)
and peroxisome proliferator-activated receptor (PPAR) in 
mitochondrial dysfunction. The expression of the PGC-1 
gene, as well as nuclear respiratory factor 2 and 
mitochondrial transcription factor A, which act downstream 
from PGC-1 were shown to be downregulated in rats with 
pressure overload due to aortic banding [13]. In a mouse 
model of transverse aortic constriction pressure overload 
hypertrophy the mean PPAR mRNA was 39% lower in the 
hypertrophied animals as compared to controls. Several of 
PPAR downstream target genes involved in fatty acid 
oxidation (FAO) were also downregulated [14]. The 
temporal pattern of the gene expression was characterized in
a rat model of progressive LVH and HF [SHHF/Mcc-facp
(SHHF) rat]. FAO enzyme mRNA levels were coordinately 
downregulated (>70%) during both the LVH and HF stages 
in the SHHF rats compared with controls. In contrast, the 
activity and steady-state levels of medium-chain acyl-CoA 
dehydrogenase, which catalyzes a rate-limiting step in FAO, 
were not significantly reduced until the HF stage, indicating 
additional control at the translational or posttranslational 
levels in the hypertrophied but nonfailing ventricle [15]. In a 
rat model of pressure overload hypertrophy, concentrations 
of free ADP, free AMP, inorganic phosphate (Pi), and 
fructose-2,6-bisphosphate (F-2,6-P2), all activators of the 
rate-limiting enzyme phosphofructokinase (PFK), were 
increased (up to 10-fold) [16]. This activation of PFK 
alongwith increased glucose uptake contributes to increased 
glycolysis in this model of pressure overload hypertrophy. 
These results can be explained by increased intracellular free 
[ADP] and [AMP], due to decreased energy reserve in LVH,
activating the AMP-activated protein kinase cascade. This, 
in turn, results in enhanced synthesis of F-2,6-P2 and 
increased sarcolemma localization of glucose transporters, 
leading to coordinated increases in glucose transport and 
activation ofPFK. 
VOLUME OVERLOAD HYPRTROPHY 
Animal Model 
  Volume overload leads to eccentric hypertrophy as a 
result of increase in cardiomyocyte length. Left ventricular 
volume overload can be of two types: low-pressure or high 
pressure [17]. Low pressure volume overload is the most 
pure form of volume overload hypertrophy in which the 
increased volume is pumped into a low pressure chamber. 
This is seen in cases of mitral regurgitation or ventricular 
septal defect with normal pulmonary artery pressures. High 
pressure volume overload occurs when the increased volume 
is pumped into a high pressure chamber such as aorta. This 
results in increased pulse pressure and this increase in 
systolic blood pressure leads to some pressure overload 
hypertrophy also. This is seen in cases of aortic 
regurgitation. There have been several animal models of pure 
volume overloaded LV hypertrophy. In a dog model, 
chordae tendineae were selectively ruptured by a forceps 
placed retrograde through the aorta across the aortic valve to 
the mitral valve apparatus [18]. This resulted in a 50 to 100% 
increase in LV end diastolic volume within 3 months [19, 
20]. These animals developed 30% eccentric hypertrophy 
and thus there was a decrease in the mass to volume ratio as 
seen in humans [19, 20]. Left ventricular dysfunction also 
occurred after 3 months due to 35% loss of the contractile 
elements [21]. An open chest open heart model of mitral 
regurgitation has also been created by cutting the chordae 
tendineae [22].  
High Energy Phosphate Levels 
  Our group has studied the myocardial energetics in a 
canine model of volume overload LV hypertrophy by tearing 
the chordae tendineae and causing severe mitral regurgitation 
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hypertrophy as compared to controls but the LV volume 
increased by 65% after approximately 1 year. These 
eccentrically hypertrophied volume overloaded hearts had 
significantly lower PCr/ATP ratios. Myocardial blood flow 
and coronary reserve were normal in MR hearts. Moreover 
hyperperfusion did not correct the abnormal energetics. 
Interestingly, unlike pressure overload hypertrophy, stresses 
imposed by exercise, pacing and dobutamine were well 
tolerated in chronic MR and did not cause further 
abnormalities in HEP metabolism.  
Substrate Utilization 
  Substrate metabolism has also been studied in volume 
overload LV hypertrophy. In a rabbit model of volume 
overload created by carotid-jugular shunt formation, 
eccentric hypertrophy developed as seen by an increase in 
LV end-diastolic dimension withoutan increase in anterior or 
posterior wall thickness [24]. The myocardial uptake of the 
fatty acid analog 
125I-iodophenyl 9-methylpentadecanoicacid 
was increased in the volume-loaded animals, suggestive of a 
greater fatty acid uptake and oxidation [24]. In contrast to 
pressure overload hypertrophy, in the early stages of cardiac 
failure in this model of volume overload eccentric 
hypertrophy, there was no downregulation of the fatty acid 




  Post-myocardial infarction hypertrophy is a complex 
phenomenon in which the stretched and dilated infarcted 
tissue increases left-ventricular volume with a combined 
volume and pressure load on non-infarcted areas [25]. Our 
laboratory has created a porcine model of postinfarction 
remodeling to study myocardial energetics [26]. Proximal 
circumflex artery was occluded in young pigs and 12 went 
on to develop left ventricular remodeling (LVR) after about 
50 days while 6 developed LVR and CHF within 20 days. 
The mean scar surface area expressed as a ratio of the total 
LV surface area was 0.16±0.02 and 0.31±0.03 in the LVR 
group and LVR+CHF group respectively. This resulted in 
ventricular hypertrophy in the LVR group as compared to 
control animals while the LVR+CHF group had the most 
hypertrophy (LVW/BW was 3.03±0.12 vs. 3.65±0.25 vs. 
4.99±0.42). It caused a decrease in ejection fraction to about 
35% and 27% in the LVR and LVR+CHF group 
respectively. LV end-systolic volume increased significantly 
in both groups of animals with remodeling and was 
significantly higher in LVR+CHF hearts than in LVR hearts. 
Both LV diastolic wall stresses and mean LV systolic wall 
stresses were significantly increased in hearts with LVR and 
were further increased in LVR+CHF hearts. 
High Energy Phosphate Levels 
  The bioenergetic abnormalities in our post-infarction LV 
hypertrophy model were characterized by a lower ATP, CP, 
creatine and PCr/ATP ratio in the LVR hearts and the 
LVR+CHF hearts had an even lower PCr/ATP ratio. The 
myocardial calculated free ADP levels were significantly 
increased only in CHF hearts. The increase in myocardial 
free ADP is associated with reductions in mitochondrial 
F0F1-ATPase protein expression [27]. These HEP levels did 
not improve with increasing blood flow with adenosine 
although the subendocardial flow reserve is impaired in CHF 
animals. There is also a loss of total adenine nucleotide pool 
in hearts with postinfarction remodeling as shown by 
accumulation of interstitial purine metabolites found in a rat 
model of postinfarction remodeling [28].  
Myocardial Oxygenation 
  It is known that the decrease of PCr/ATP in LVR animal 
during dobutamine infusion is not the result of insufficient 
myocardial oxygen availability [29]. Furthermore, in CHF 
hearts, the low basal PCr/ATP and the attenuated response to 
dobutamine occurred in the absence of myocardial hypoxia, 
indicating that the HEP and contractile abnormalities were 
not the result of insufficient oxygen availability [29].  
Myocardial Creatine Kinase Kinetics and Isoform 
Expression 
  It has been shown that the CK-MM and CK-
mitochondrial protein levels are decreased in animals with 
pos-infarction hypertrophy while the CK-MB levels are 
increased [30]. However, the total CK activity did not 
change significantly in the animals with LVH [30]. These 
changes may partially contribute to the altered HEP 
metabolism in hearts with postinfarction remodeling. 
Subsequently, it has been shown that the CK flux rates are 
decreased in hearts with postinfarction remodeling but this 
change does not seem to limit their response to dobutamine 
[31]. However, the animals that develop CHF have further 
decreased high energy phosphates and CK flux rate and 
these changes may contribute to their decreased response to 
dobutamine [31].  
Substrate Utilization 
  Substrate utilization in post-infarction LV hypertrophy 
also exhibits shifts in fatty acid and glucose metabolism. In a 
post-infarction rat model, glucose oxidation was increased 
by 84% while there was no change in palmitate oxidation 8 
weeks after MI [32]. The pattern of gene expression 
regulating substrate utilization could change as LV 
remodeling progresses to heart failure, so the same group 
followed these animals for 20 weeks [33]. At 8 weeks, when 
left ventricular hypertrophy was present without signs of 
heart failure, myocardial mRNA expression of glucose
transporters (GLUT-1 and GLUT-4) was not altered, 
whereas mRNA expression of medium-chain acyl-CoA 
dehydrogenase (MCAD) was significantly reduced in the 
peri-infarct region. In hearts exhibiting heart failure 20 
weeks after infarct-induction there was a change of both 
mRNA and protein content of GLUT-1 and MCAD [33]. 
Infarct Borderzone Energetic Abnormalities 
  Post-infarction hypertrophy differs significantly from 
other forms of hypertrophy because of the presence of a 
discrete scar region. The alterations in myocardial HEP and 
mtATPase have been shown to be substantially more severe 
in the peri-infarct region than in the remote zone of hearts 
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abnormalities mirror the contractile dysfunctionof the border 
zone myocardium and may play a role in the eventual
transition to heart failure. The bioenergetic and contractile 
abnormalities of the BZ, which are triggered by elevated 
regional wall stress, may extend laterally and eventually
involve the entire LV, thereby leading to global LV 
dysfunctionand the development of CHF [35]. 
HUMAN CLINICAL STUDIES 
 Clinical studies of cardiac energy metabolism 
(summarized in Table 2) have shown similar results to pre-
viously obtained from animal studies.  
  The PCr/ATP ratio is decreased in patients with pressure 
induced LVH [36, 37]. In a study of patients with diastolic 
dysfunction secondary to hypertensive heart disease, patients 
showed higher LV mass (98±28 g/m
2) than healthy control 
subjects (73±13 g/m
2, P<0.01). LV filling was impaired in 
patients, reflected by a decreased peak rate of wall thinning 
(PRWThn), E/A ratio, early peak filling rate, and early 
deceleration peak (all P<0.05), whereas systolicfunction was 
still normal. The myocardial PCr/ATP ratio determined in 
patients at rest (1.20±0.18) andduring stress (0.95±0.25) was 
lower than corresponding values obtained from healthy 
control subjects at rest (1.39±0.17,P<0.05) and during stress 
(1.16±0.18,  P<0.05). The PCr/ATP ratio correlated 
significantly with PRWThn (r=-0.55,  P<0.01), early 
deceleration peak (r=-0.56,  P<0.01), and with the rate-
pressureproduct (r=-0.53, P<0.001). Creatine kinase kinetics 
is also affected in patients with pressure induced LVH. In 
hypertrophic human hearts in the absence of CHF, ATP flux 
through CK is reduced by 30% in LVH patients, and this 
reduction can be accounted for by a proportionate loss of 
substrate (PCr) [38]. Patients with a similar degree of LVH 
but who additionally had CHF exhibited no greater 
reductions in PCr and ATP than those without CHF. 
However, the CK pseudo first-order rate constant was 
markedly depressed in these CHF patients compared with 
that of normal subjects and of LVH patients without CHF.
Consequently, myocardial CK flux in LVH patients with 
CHF declined to approximately one third that of normal 
subjects [38]. These data provide direct evidence that a 
defect in the kinetics of ATP turnover through CK and not 
the pool sizes per se may distinguish failing and nonfailing 
human hypertrophic myocardium.  
  PCr/ATP is also lower in humans with volume overload 
hypertrophy such as chronic MR and the severity of 
abnormal myocardial energetics is linked to disease severity 
as measured by dimensional indexes of left ventricular 
dilatation and hypertrophy [39]. In patients with dilated 
cardiomyopathy, PCr/ATP ratio was lower and seemed to 
correlate with worsening heart failure as assessed by NYHA 
class [40]. It has also been suggested that PCr/ATP ratios are 
a predictor of both total and cardiovascular mortality in 
patients with dilated cardiomyopathy [41]. In another study, 
patients with DCM were also shown to have a reduction in 
absolute concentrations of PCr by 51% and ATP by 35% 
[42]. CK activity is also lower in patients with DCM 
undergoing transplantation and this was associated with 
decreased expression of CK-MM and increased expression 
of CK-MB [43].  
  There have been some myocardial energetic studies in 
ischemic heart disease patients. In patients with ischemic 
cardiomyopathy, PCr/ATP ratio was significantly lower as 
compared to controls [44]. Cardiac energy metabolism is 
normal at rest in patients with chronic myocardial infarction 
without heart failure [40]. However, this ratio significantly 
decreases during exercise [45]. In another study, patients 
with ischemic heart disease had significantly lower PCr 
content if they had either a reversible or fixed defect on 
exercise 
201Tl scintigraphy, but ATP content was decreased 
significantly only in subjects with fixed thallium defects 
[46].  
  The data on substrate metabolism in patients with LV 
hypertrophy is scant, while in patients with congestive heart 
failure it is conflicting. In a study of NYHA class II and III 
patients, fatty acid uptake was increased while glucose 
uptake was decreased [47]. This was associated with a 50% 
increase in lipid oxidation as measured by transmyocardial 
respiratory quotient and a 60% decrease in carbohydrate 
oxidation. It was also demonstrated in a PET study that 
patients with NYHA class III heart failure (majority 
ischemic) had greater myocardial uptake of a radiolabeled 
fatty acid analog and less uptake of radiolabeled 
deoxyglucose [48]. On the other hand, in dilated 
Table 2.  Myocardial Energetics in Humans with Left Ventricular Hypertrophy 
  Pressure Overload Hypertrophy  Volume Overload Hypertrophy  Post-infarction Hypertrophy 
PCr/ATP under baseline conditions  Decreased Decreased Decreased 
PCr/ATP under increased workload Decreased  -  Decreased 
CK forward rate constant  No change with LVH but decreased
with LVH and CHF. 
- - 
CK flux rate  Decreased  -  - 
CK-MM isoform  -  Decreased  - 
CK-MB  isoform  - Increased - 
Substrate Utilization 
Conflicting data across groups but it seems that in early stages of heart 
failure there is normal or slightly elevated rate of fatty acid oxidation with a
dramatic downregulation in advanced heart failure. 
PCr, Phosphocreatine; ATP, Adenosine Triphosphate; CK, Creatine Kinase. Myocardial Energetics in Left Ventricular Hypertrophy  Current Cardiology Reviews, 2009, Vol. 5, No. 3     249
cardiomyopathy patients, fatty acid utilization was decreased 
and myocardial glucose metabolism was increased [49]. 
Overall, it is believed that in the early stages of heart failure 
there is a normal (or slightly elevated) rate of fatty acid 
oxidation, with a dramatic downregulation of fatty acid 
oxidation in advancedor end-stage heart failure [50]. 
CONCLUSION 
  Left ventricular hypertrophy is characterized by deran-
gements in cardiac energy metabolism including lower 
PCr/ATP, abnormal creatine kinase kinetics and deranged 
substrate utilization. The PCr/ATP is significantly decreased 
in hearts with LVH and the severity of this abnormality is 
proportional to the degree of cardiac hypertrophy and 
accompanying LV dysfunction. These myocardial energetic 
abnormalities are also not due to a persistent myocardial 
ischemic state. There is a profound heterogeneity in the 
myocardial energy metabolism in hearts with postinfarction 
LV remodeling with the most severe abnormality occurring 
in the inner layers of the periscar border zone (BZ). 
Increased wall stress and overstretching of myocytes could 
contribute to the observed decrease in energetic efficiency in 
the BZ. CHF probably develops as this energetically 
inefficient BZ expands over time and eventually involves the 
entire heart.  
  Preserving myocardial energetic efficiency through 
metabolic therapies is a promising therapy for heart failure in 
the future. To achieve this goal, further molecular studies are 
required to understand the mechanisms underlying the 
myocardial energetic abnormalities. Furthermore, develop-
ment of effective and time feasible methods of non-invasive 
NMR spectroscopy along with magnetic resonance imaging 
(MRI) will allow us to study temporal changes in myocardial 
energetics in patients with LVH and CHF and correlate these 
with structural changes in the hearts. Finally, new drugs need 
to be developed and tested that target energy metabolism 
pathways with the ultimate goal of improving survival in 
patient with LVH and CHF. 
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